Compare Abeona Therapeutics Inc (ABEO) vs Kohl's Corporation (KSS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Kohl's Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Kohl's Corporation trades at $15.95 (market cap $1.90B). The key difference: Kohl's Corporation is far larger — about 5.1× Abeona Therapeutics Inc's market cap, and Kohl's Corporation pays a 2.98% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | KSS | |
|---|---|---|
Market Cap | $373.32M | $1.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $24.71 |
52-Week Low | $4.17 | $9.08 |
Enterprise Value | $228.22M | $8.00B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Kohl's (KSS) trades at $16.76, down 7.86% on the day, with the stock showing mixed technical signals amid a broader turnaround effort. The company demonstrates improving fundamentals with recent earnings beats and proprietary brand growth, though revenue continues to decline. Valuation metrics appear attractive with a P/E of 7.1 and P/S of 0.12, while technical indicators show bullish moving averages but neutral oscillators.
Kohl's presents a compelling value opportunity with strong proprietary brand momentum and cost controls, though execution risks remain high amid declining sales and intense retail competition. The stock's current price aligns with analyst consensus targets, suggesting limited near-term upside without clearer evidence of sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
